Ipsen SA - Company Profile
Powered by
All the data and insights you need on Ipsen SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Ipsen SA Strategy Report
- Understand Ipsen SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Ipsen SA patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
WO2022189807A2 | Application | MODIFIED CLOSTRIDIAL NEUROTOXINS | A61K38/164; A61P17/00; C07K14/33 | September 15, 2022 |
EP2073789B8 | Grant | STABILE ZUSAMMENSETZUNG MIT ANABOLISCHEM KNOCHENPROTEIN, UND ZWAR EINEM PTHRP-ANALOGON, SOWIE DEREN VERWENDUNG | A61K38/16; A61K38/29; A61K47/02; A61K47/14; A61K9/00; A61K9/0019; A61K9/08; A61P19/00; A61P19/08; A61P19/10; A61P31/04; Y02A50/30 | September 14, 2022 |
CN115028619A | Application | SMYD抑制剂 | A61K31/404; A61K31/517; A61P35/00; A61P35/02; A61P43/00; C07C271/18; C07D205/04; C07D209/08; C07D211/34; C07D213/81; C07D213/82; C07D231/14; C07D233/90; C07D237/24; C07D241/26; C07D249/04; C07D261/10; C07D263/34; C07D275/03; C07D277/56; C07D401/12; C07D401/14; C07D403/12; C07D403/14; C07D413/12; C07D417/14; C07D451/04 | September 09, 2022 |
AU2021224855A1 | Application | SETD2 inhibitors and related methods and uses, including combination therapies | A61K31/496; A61K31/5377; A61K31/545; A61K45/06; C07D487/04 | September 08, 2022 |
US20220281854A1 | Application | COMBINATION THERAPY FOR TREATING CANCER | A61K31/436; A61K31/4412; A61K31/4439; A61K31/444; A61K31/4745; A61K31/53; A61K31/5355; A61K31/5377; A61K31/573; A61K31/675; A61K31/704; A61K31/7068; A61K33/243; A61K45/06; A61P35/00; C07D213/64; C07D405/12; C07D413/14 | September 08, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer